Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21128574 | 0.79 | IDO1 (0.74) | IDO1POLBSMN1; SMN2CYP3A4SCN9A | |
| SCHEMBL1502406 | 0.78 | IDO1 (0.64) | IDO1POLBSMN1; SMN2CYP3A4SCN9A | |
| SCHEMBL872414 | 0.78 | IDO1 (1.00) | IDO1CYP3A4SCN9ACYP2E1CYP2D6 | |
| SCHEMBL25214286 | 0.78 | IDO1 (0.64) | IDO1POLBSMN1; SMN2CYP3A4SCN9A | |
| SCHEMBL871586 | 0.78 | IDO1 (0.64) | IDO1POLBSMN1; SMN2CYP3A4SCN9A | |
| SCHEMBL25262025 | 0.78 | IDO1 (0.64) | IDO1POLBSMN1; SMN2CYP3A4SCN9A | |
| SCHEMBL1949479 | 0.78 | IDO1 (1.00) | IDO1POLBSMN1; SMN2CYP3A4SCN9A | |
| SCHEMBL9783348 | 0.77 | IDO1 (0.61) | IDO1POLBSMN1; SMN2CYP3A4SCN9A | |
| SCHEMBL9783334 | 0.77 | IDO1 (0.61) | IDO1POLBSMN1; SMN2CYP3A4SCN9A | |
| SCHEMBL872388 | 0.76 | POLB (1.00) | IDO1POLBSMN1; SMN2CYP3A4CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | GIVAUDAN SA (CH) | 2026-01-20 | — | — | US | claimed |
| EP-4045491-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | Givaudan SA (CH) | 2022-08-24 | — | — | EP | disclosed |
| EP-3032625-B1 | FUEL CELL SEPARATOR | NISSHINBO CHEMICAL INC (JP) | 2020-01-08 | — | — | EP | disclosed |
| WO-2018028491-A1 | INDOLEAMINE2,3-DIOXYGENASE INHIBITORS AND USES THEREOF IN PHARMACY | 苏州国匡医药科技有限公司 | 2018-02-15 | — | — | WO | disclosed |
| EP-3264506-A1 | METHOD FOR PRODUCING A FUEL CELL SEPARATOR | Nisshinbo Chemical Inc. (JP) | 2018-01-03 | — | — | EP | disclosed |
| EP-2458667-B1 | FUEL CELL SEPARATOR | NISSHINBO CHEMICAL INC (JP) | 2017-05-24 | — | — | EP | disclosed |
| EP-2763223-B1 | POROUS SEPARATOR FOR FUEL CELLS | NISSHINBO CHEMICAL INC (JP) | 2016-11-16 | — | — | EP | disclosed |
| EP-3032625-A1 | FUEL CELL SEPARATOR | Nisshinbo Chemical Inc. (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-20160156044-A1 | FUEL CELL SEPARATOR | NISSHINBO CHEMICAL INC. (JP) | 2016-06-02 | — | — | US | disclosed |
| EP-2763223-A1 | POROUS SEPARATOR FOR FUEL CELLS | Nisshinbo Chemical Inc. (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8372192-B2 | Fuel cell separator | NISSHINBO CHEMICAL INC. (JP) | 2013-02-12 | — | — | US | disclosed |
| EP-2458667-A1 | FUEL CELL SEPARATOR | Nisshinbo Chemical Inc. (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20120077111-A1 | FUEL CELL SEPARATOR | NISSHINBO CHEMICAL INC. (JP) | 2012-03-29 | — | — | US | disclosed |
| US-7790741-B2 | Imidazothiazoles and imidazoxazoles | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | TRPM8, TRPM7, TRPM4 | IDO1 1885/4885POLB 4565/4885SMN1; SMN2 2759/4885 |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | MAP3K1, MAP3K19, MAP3K5 | IDO1 1304/4885POLB 2315/4885SMN1; SMN2 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.